| NCT03175939 |
Elimination of Adjuvant Chemotherapy for Selected Stage II and III Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03175939 |
Completed |
Sun Yat-sen University |
2008-12-31 |
| NCT04453813 |
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT04453813 |
Recruiting |
Sun Yat-sen University |
2025-07-31 |
| NCT03682055 |
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) |
https://ClinicalTrials.gov/show/NCT03682055 |
Active, not recruiting |
Cullinan Oncology, LLC |
2021-10-31 |
| NCT03389295 |
Reduced Target Delineation and Radiation Doses Chemoradiotherapy for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03389295 |
Completed |
Fudan University |
2019-04-30 |
| NCT03346109 |
To Study the Feasibility and Quality of Life of Medial Group Retropharyngeal Node Sparing in Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03346109 |
Recruiting |
Sun Yat-sen University |
2019-06-30 |
| NCT03366415 |
Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC |
https://ClinicalTrials.gov/show/NCT03366415 |
Recruiting |
Fudan University |
2023-12-31 |
| NCT03707509 |
Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03707509 |
Active, not recruiting |
Jiangsu HengRui Medicine Co., Ltd. |
2021-08-01 |
| NCT03321539 |
Phase â…¢ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03321539 |
Recruiting |
Sun Yat-sen University |
2020-12-31 |
| NCT03283293 |
Target Volume Delineation After NACT in LA-NPCarcinoma Patients Treated With NACT+ CCRT |
https://ClinicalTrials.gov/show/NCT03283293 |
Completed |
Sun Yat-sen University |
2007-04-30 |
| NCT03282617 |
Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03282617 |
Recruiting |
National University Hospital, Singapore |
2019-08-14 |
| NCT03267498 |
Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC) |
https://ClinicalTrials.gov/show/NCT03267498 |
Recruiting |
University of California, San Francisco |
2020-11-30 |
| NCT03196869 |
the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer |
https://ClinicalTrials.gov/show/NCT03196869 |
Recruiting |
Guiyang Medical University |
2019-04-12 |
| NCT03177174 |
Different Chemotherapy Protocols Combined With Intensity Modulated Radiation Therapy in Patients With Locally Advanced Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03177174 |
Completed |
Chinese PLA General Hospital |
2020-01-01 |
| NCT03144661 |
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies |
https://ClinicalTrials.gov/show/NCT03144661 |
Recruiting |
Incyte Corporation |
2021-02-28 |
| NCT03129412 |
Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions |
https://ClinicalTrials.gov/show/NCT03129412 |
Recruiting |
Zhejiang Cancer Hospital |
2023-04-23 |
| NCT03121716 |
A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects |
https://ClinicalTrials.gov/show/NCT03121716 |
Active, not recruiting |
Jiangsu HengRui Medicine Co., Ltd. |
2019-04-30 |
| NCT03097939 |
Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03097939 |
Recruiting |
National Cancer Centre, Singapore |
2019-11-30 |
| NCT03096808 |
Adaptive Radiotherapy for Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT03096808 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-03-15 |
| NCT03074513 |
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors |
https://ClinicalTrials.gov/show/NCT03074513 |
Recruiting |
M.D. Anderson Cancer Center |
2021-03-31 |
| NCT03047525 |
Study of DC-CTL Combined With CIK for Advanced Solid Tumor |
https://ClinicalTrials.gov/show/NCT03047525 |
Recruiting |
Harbin Medical University |
2019-01-01 |
| NCT03047265 |
Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03047265 |
Active, not recruiting |
Sun Yat-sen University |
2025-12-01 |
| NCT03044743 |
PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies |
https://ClinicalTrials.gov/show/NCT03044743 |
Recruiting |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2020-03-31 |
| NCT03020329 |
Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03020329 |
Recruiting |
Sun Yat-sen University |
2020-12-30 |
| NCT03007836 |
High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal Cancer |
https://ClinicalTrials.gov/show/NCT03007836 |
Completed |
Fuda Cancer Hospital, Guangzhou |
2017-12-01 |
| NCT02973386 |
Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients |
https://ClinicalTrials.gov/show/NCT02973386 |
Recruiting |
Sun Yat-sen University |
2020-12-31 |
| NCT02958111 |
Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02958111 |
Active, not recruiting |
Sun Yat-sen University |
2021-12-31 |
| NCT02940925 |
TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02940925 |
Active, not recruiting |
Sun Yat-sen University |
2019-10-14 |
| NCT02915445 |
EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer |
https://ClinicalTrials.gov/show/NCT02915445 |
Recruiting |
Sichuan University |
2020-07-31 |
| NCT02915432 |
The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC |
https://ClinicalTrials.gov/show/NCT02915432 |
Active, not recruiting |
Shanghai Junshi Bioscience Co., Ltd. |
2019-09-30 |
| NCT02874651 |
ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy |
https://ClinicalTrials.gov/show/NCT02874651 |
Recruiting |
Sun Yat-sen University |
2021-06-30 |
| NCT02871518 |
Two Cycles Versus Three Cyclle of CCRT for Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02871518 |
Recruiting |
Sun Yat-sen University |
2018-07-31 |
| NCT02794077 |
Cyclophosphamide for Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02794077 |
Completed |
The University of Hong Kong |
2015-12-31 |
| NCT02776124 |
Effect of Oral Supplements on the Nutritional Status of Locally Advanced Nasopharyngeal Carcinoma Patients |
https://ClinicalTrials.gov/show/NCT02776124 |
Completed |
Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University |
2016-08-31 |
| NCT02759250 |
A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC) |
https://ClinicalTrials.gov/show/NCT02759250 |
Completed |
argenx BVBA |
2018-04-25 |
| NCT02698111 |
Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02698111 |
Recruiting |
Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
2020-06-30 |
| NCT02642107 |
Individualized Elective Neck Irradiation Based on MRI in NPC Patients |
https://ClinicalTrials.gov/show/NCT02642107 |
Active, not recruiting |
Sun Yat-sen University |
2018-05-31 |
| NCT02636231 |
Endostar for Locally Recurrent Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02636231 |
Recruiting |
Sun Yat-sen University |
2019-12-31 |
| NCT02633202 |
Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era |
https://ClinicalTrials.gov/show/NCT02633202 |
Recruiting |
Sun Yat-sen University |
2019-12-31 |
| NCT02633176 |
Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02633176 |
Recruiting |
Sun Yat-sen University |
2023-01-31 |
| NCT02627807 |
Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02627807 |
Active, not recruiting |
Sun Yat-sen University |
2020-12-31 |
| NCT02611960 |
Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122) |
https://ClinicalTrials.gov/show/NCT02611960 |
Active, not recruiting |
Merck Sharp & Dohme Corp. |
2020-11-30 |
| NCT02610556 |
Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02610556 |
Recruiting |
Sun Yat-sen University |
2020-01-31 |
| NCT02610010 |
Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02610010 |
Recruiting |
Sun Yat-sen University |
2022-11-30 |
| NCT02608073 |
A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer |
https://ClinicalTrials.gov/show/NCT02608073 |
Completed |
Hoffmann-La Roche |
2009-11-30 |
| NCT02605967 |
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02605967 |
Active, not recruiting |
Novartis |
2020-08-27 |
| NCT02590133 |
A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC |
https://ClinicalTrials.gov/show/NCT02590133 |
Recruiting |
Sun Yat-sen University |
2018-12-31 |
| NCT02584790 |
NBI to Detect Post-RT Mucosal Residual NPC |
https://ClinicalTrials.gov/show/NCT02584790 |
Completed |
Pamela Youde Nethersole Eastern Hospital |
2017-04-30 |
| NCT02582008 |
Bupropion Hydrochloride or Patient’s Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy |
https://ClinicalTrials.gov/show/NCT02582008 |
Active, not recruiting |
Wake Forest University Health Sciences |
2019-09-28 |
| NCT03403829 |
Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage |
https://ClinicalTrials.gov/show/NCT03403829 |
Recruiting |
Fudan University |
2020-12-31 |
| NCT02035527 |
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT02035527 |
Completed |
Ohio State University Comprehensive Cancer Center |
2017-04-20 |
| NCT03387774 |
Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients |
https://ClinicalTrials.gov/show/NCT03387774 |
Recruiting |
Sun Yat-sen University |
2020-12-31 |
| NCT02538510 |
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT02538510 |
Active, not recruiting |
University of Washington |
2019-09-28 |
| NCT02523430 |
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02523430 |
Completed |
Fuda Cancer Hospital, Guangzhou |
2016-06-30 |
| NCT02512315 |
A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02512315 |
Recruiting |
Sun Yat-sen University |
2024-12-31 |
| NCT02507154 |
Reactivating NK Cells in Treating Refractory Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT02507154 |
Recruiting |
National University Hospital, Singapore |
2019-08-31 |
| NCT02500940 |
Comparison the Effects of Different Neoadjuvant Chemotherapy Regimen on Acute Toxicity, Tumor Response, and Survival in Patients With Advanced Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02500940 |
Recruiting |
Taichung Veterans General Hospital |
2016-05-31 |
| NCT02460887 |
The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT |
https://ClinicalTrials.gov/show/NCT02460887 |
Active, not recruiting |
Sun Yat-sen University |
2021-06-30 |
| NCT02460419 |
Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02460419 |
Recruiting |
Sun Yat-sen University |
2020-05-31 |
| NCT02456506 |
Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma. |
https://ClinicalTrials.gov/show/NCT02456506 |
Active, not recruiting |
Sun Yat-sen University |
2022-12-31 |
| NCT02434614 |
Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02434614 |
Active, not recruiting |
Guilin Medical University, China |
2021-05-31 |
| NCT02363400 |
A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA |
https://ClinicalTrials.gov/show/NCT02363400 |
Enrolling by invitation |
National Health Research Institutes, Taiwan |
2019-12-31 |
| NCT02360501 |
Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02360501 |
Completed |
Sun Yat-sen University |
2016-03-31 |
| NCT02339558 |
Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer |
https://ClinicalTrials.gov/show/NCT02339558 |
Completed |
National Cancer Institute (NCI) |
2018-06-16 |
| NCT02309437 |
Early Use of Opioid in Radiation Mucositis |
https://ClinicalTrials.gov/show/NCT02309437 |
Completed |
Affiliated Cancer Hospital & Institute of Guangzhou Medical University |
2017-12-31 |
| NCT02287311 |
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) |
https://ClinicalTrials.gov/show/NCT02287311 |
Recruiting |
Baylor College of Medicine |
2021-02-28 |
| NCT02269943 |
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02269943 |
Completed |
Celgene |
2017-04-20 |
| NCT02143388 |
Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial |
https://ClinicalTrials.gov/show/NCT02143388 |
Active, not recruiting |
Sun Yat-sen University |
2018-07-31 |
| NCT02135042 |
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA |
https://ClinicalTrials.gov/show/NCT02135042 |
Recruiting |
NRG Oncology |
2021-07-31 |
| NCT02123511 |
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy |
https://ClinicalTrials.gov/show/NCT02123511 |
Completed |
Mayo Clinic |
2016-03-22 |
| NCT02113878 |
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck |
https://ClinicalTrials.gov/show/NCT02113878 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2020-12-31 |
| NCT02113423 |
Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02113423 |
Completed |
Fujian Cancer Hospital |
2009-06-30 |
| NCT02111460 |
Chemotherapy Combined With Radiotherapy vs Chemotherapy Alone for Distant Metastatic Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02111460 |
Active, not recruiting |
Sun Yat-sen University |
2019-08-31 |
| NCT02065362 |
TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC |
https://ClinicalTrials.gov/show/NCT02065362 |
Active, not recruiting |
Baylor College of Medicine |
2017-03-31 |
| NCT01316757 |
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer |
https://ClinicalTrials.gov/show/NCT01316757 |
Completed |
Fox Chase Cancer Center |
2015-04-07 |
| NCT01309633 |
Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC) |
https://ClinicalTrials.gov/show/NCT01309633 |
Completed |
National University Hospital, Singapore |
2019-03-11 |
| NCT01271439 |
Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT01271439 |
Completed |
Sun Yat-sen University |
2012-06-30 |
| NCT03353467 |
Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients |
https://ClinicalTrials.gov/show/NCT03353467 |
Recruiting |
Sun Yat-sen University |
2020-10-01 |
| NCT02012062 |
Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC |
https://ClinicalTrials.gov/show/NCT02012062 |
Completed |
Fudan University |
2016-03-31 |
| NCT01937793 |
Swallowing Exercises for Nasopharyngeal Cancer After Radiation Therapy |
https://ClinicalTrials.gov/show/NCT01937793 |
Completed |
National Taiwan University Hospital |
2013-12-31 |
| NCT01872962 |
Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT01872962 |
Active, not recruiting |
Sun Yat-sen University |
2018-11-30 |
| NCT01865201 |
Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis |
https://ClinicalTrials.gov/show/NCT01865201 |
Completed |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2011-10-31 |
| NCT01847326 |
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT01847326 |
Recruiting |
University of Chicago |
2021-04-30 |
| NCT01817023 |
The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT |
https://ClinicalTrials.gov/show/NCT01817023 |
Recruiting |
Chinese Academy of Medical Sciences |
2019-07-30 |
| NCT01806675 |
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy |
https://ClinicalTrials.gov/show/NCT01806675 |
Completed |
Stanford University |
2016-12-07 |
| NCT01800071 |
A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT01800071 |
Completed |
Cancer Research UK |
2017-03-10 |
| NCT01797900 |
The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT |
https://ClinicalTrials.gov/show/NCT01797900 |
Completed |
Chinese Academy of Medical Sciences |
2014-09-30 |
| NCT01712919 |
Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC) |
https://ClinicalTrials.gov/show/NCT01712919 |
Completed |
Jiangsu Cancer Institute & Hospital |
2014-03-31 |
| NCT01637194 |
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT01637194 |
Completed |
Fox Chase Cancer Center |
2011-07-31 |
| NCT01621880 |
Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT01621880 |
Completed |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2015-08-31 |
| NCT01616849 |
Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT01616849 |
Completed |
Sun Yat-sen University |
2015-07-31 |
| NCT01596868 |
GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China |
https://ClinicalTrials.gov/show/NCT01596868 |
Completed |
Fourth Military Medical University |
2013-10-31 |
| NCT01540136 |
Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT01540136 |
Completed |
Sun Yat-sen University |
2014-05-31 |
| NCT01534585 |
Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT01534585 |
Completed |
Taizhou Hospital |
2013-02-28 |
| NCT01469429 |
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. |
https://ClinicalTrials.gov/show/NCT01469429 |
Completed |
Ohio State University Comprehensive Cancer Center |
2014-09-17 |
| NCT01462474 |
Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT01462474 |
Completed |
Jiangsu HengRui Medicine Co., Ltd. |
2015-08-31 |
| NCT01449942 |
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT01449942 |
Completed |
Xiangya Hospital of Central South University |
2011-04-30 |
| NCT01447056 |
Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases |
https://ClinicalTrials.gov/show/NCT01447056 |
Completed |
Baylor College of Medicine |
2015-03-31 |
| NCT01439724 |
Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients |
https://ClinicalTrials.gov/show/NCT01439724 |
Completed |
Instituto Nacional de Cancer, Brazil |
2008-06-30 |
| NCT01392235 |
Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC) |
https://ClinicalTrials.gov/show/NCT01392235 |
Completed |
Jiangsu HengRui Medicine Co., Ltd. |
2015-04-30 |
| NCT01370070 |
MK-2206 in Recurrent Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT01370070 |
Completed |
Chinese University of Hong Kong |
2016-12-31 |
| NCT01365169 |
Post-op Wellness Program for Pancreatic Cancer Patients That Uses Patient Feedback and Real-time Provider Monitoring |
https://ClinicalTrials.gov/show/NCT01365169 |
Recruiting |
M.D. Anderson Cancer Center |
2025-02-25 |
| NCT01349933 |
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT01349933 |
Completed |
National Cancer Institute (NCI) |
2013-10-31 |
| NCT01344356 |
Stereotactic Body Radiotherapy for Head and Neck Tumors |
https://ClinicalTrials.gov/show/NCT01344356 |
Completed |
Mercy Research |
2018-05-31 |
| NCT01334177 |
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck |
https://ClinicalTrials.gov/show/NCT01334177 |
Completed |
University of Washington |
2014-06-30 |
| NCT01326559 |
Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC) |
https://ClinicalTrials.gov/show/NCT01326559 |
Completed |
Hong Kong Nasopharyngeal Cancer Study Group Limited |
2016-12-31 |
| NCT04447612 |
Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT04447612 |
Recruiting |
The University of Hong Kong |
2023-12-31 |
| NCT04437329 |
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT04437329 |
Recruiting |
Affiliated Cancer Hospital & Institute of Guangzhou Medical University |
2028-06-30 |
| NCT04436965 |
Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition |
https://ClinicalTrials.gov/show/NCT04436965 |
Recruiting |
Sun Yat-sen University |
2024-06-15 |
| NCT04405622 |
Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. |
https://ClinicalTrials.gov/show/NCT04405622 |
Recruiting |
Sun Yat-sen University |
2021-05-31 |
| NCT04398056 |
Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT04398056 |
Recruiting |
Sun Yat-sen University |
2021-04-01 |
| NCT04396886 |
Bintrafusp Alfa in Previously Treated Patients With Recurrent and Metastatic (R/M) Non-keratinizing Nasopharyngeal Carcinoma (NPC) |
https://ClinicalTrials.gov/show/NCT04396886 |
Recruiting |
The University of Hong Kong |
2024-02-23 |
| NCT04350190 |
Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT04350190 |
Recruiting |
Guilin Medical University, China |
2021-05-30 |
| NCT04282070 |
SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT04282070 |
Recruiting |
Jiangsu HengRui Medicine Co., Ltd. |
2021-04-16 |
| NCT04220528 |
Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC |
https://ClinicalTrials.gov/show/NCT04220528 |
Recruiting |
Fujian Cancer Hospital |
2023-06-01 |
| NCT04136886 |
Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT04136886 |
Recruiting |
Sun Yat-sen University |
2027-12-31 |
| NCT04073784 |
Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma. |
https://ClinicalTrials.gov/show/NCT04073784 |
Recruiting |
Sun Yat-sen University |
2021-01-01 |
| NCT04072107 |
EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR) |
https://ClinicalTrials.gov/show/NCT04072107 |
Recruiting |
Sun Yat-sen University |
2022-12-31 |
| NCT04061278 |
A Multicenter, Prospective, Phase III Randomized Controlled Clinical Study for the Treatment of N2-3 Nasopharyngeal Carcinoma Patients |
https://ClinicalTrials.gov/show/NCT04061278 |
Recruiting |
Second Affiliated Hospital, School of Medicine, Zhejiang University |
2022-06-30 |
| NCT04015661 |
Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC |
https://ClinicalTrials.gov/show/NCT04015661 |
Recruiting |
Fuzhou General Hospital |
2020-12-01 |
| NCT03930498 |
Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03930498 |
Recruiting |
Sun Yat-sen University |
2021-11-30 |
| NCT03925896 |
Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients |
https://ClinicalTrials.gov/show/NCT03925896 |
Recruiting |
Sun Yat-sen University |
2020-08-01 |
| NCT03925090 |
Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients |
https://ClinicalTrials.gov/show/NCT03925090 |
Recruiting |
Sun Yat-sen University |
2021-10-31 |
| NCT03924986 |
Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer |
https://ClinicalTrials.gov/show/NCT03924986 |
Recruiting |
BeiGene |
2021-08-31 |
| NCT03923842 |
Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours |
https://ClinicalTrials.gov/show/NCT03923842 |
Recruiting |
Gruppo Oncologico del Nord-Ovest |
2021-09-30 |
| NCT03919552 |
Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03919552 |
Recruiting |
Nanfang Hospital of Southern Medical University |
2023-01-31 |
| NCT03915132 |
Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03915132 |
Recruiting |
Chinese Academy of Medical Sciences |
2020-05-01 |
| NCT03908372 |
Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03908372 |
Recruiting |
Chinese Academy of Medical Sciences |
2021-05-31 |
| NCT03907826 |
Programmed Death-1 (PD-1) Antibody Combined With IMRT in Recurrent Nasopharyngeal Carcinoma Patients |
https://ClinicalTrials.gov/show/NCT03907826 |
Recruiting |
Sun Yat-sen University |
2021-11-30 |
| NCT03906058 |
Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy |
https://ClinicalTrials.gov/show/NCT03906058 |
Recruiting |
Sun Yat-sen University |
2021-04-29 |
| NCT03904225 |
Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis |
https://ClinicalTrials.gov/show/NCT03904225 |
Recruiting |
Zhejiang Cancer Hospital |
2022-12-31 |
| NCT03891953 |
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. |
https://ClinicalTrials.gov/show/NCT03891953 |
Recruiting |
Novartis |
2022-11-28 |
| NCT03890185 |
Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC |
https://ClinicalTrials.gov/show/NCT03890185 |
Active, not recruiting |
King Faisal Specialist Hospital & Research Center |
2020-12-31 |
| NCT03876574 |
Hepatic Artery Infusion Pump for NPC Liver Metastases |
https://ClinicalTrials.gov/show/NCT03876574 |
Completed |
Xiangya Hospital of Central South University |
2017-12-31 |
| NCT03854838 |
IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma. |
https://ClinicalTrials.gov/show/NCT03854838 |
Recruiting |
Sun Yat-sen University |
2020-06-30 |
| NCT03849469 |
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03849469 |
Recruiting |
Xencor, Inc. |
2026-09-30 |
| NCT03840421 |
GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03840421 |
Recruiting |
Sun Yat-sen University |
2023-02-14 |
| NCT03839602 |
Delineation of Reducing Clinical Target Volume for Early-stage Nasopharyngeal Carcinoma Patients |
https://ClinicalTrials.gov/show/NCT03839602 |
Completed |
Sun Yat-sen University |
2006-10-31 |
| NCT03837808 |
Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03837808 |
Recruiting |
Sun Yat-sen University |
2022-02-11 |
| NCT03788499 |
Using Massage of Maxillofacial and Oral Cavity to Prevent Radioactive Oral Mucositis |
https://ClinicalTrials.gov/show/NCT03788499 |
Recruiting |
Xinqiao Hospital of Chongqing |
2021-02-27 |
| NCT03769467 |
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) |
https://ClinicalTrials.gov/show/NCT03769467 |
Recruiting |
Atara Biotherapeutics |
2023-09-30 |
| NCT03752398 |
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) |
https://ClinicalTrials.gov/show/NCT03752398 |
Recruiting |
Xencor, Inc. |
2024-09-30 |
| NCT03734809 |
NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer |
https://ClinicalTrials.gov/show/NCT03734809 |
Recruiting |
Chinese University of Hong Kong |
2022-12-31 |
| NCT03720340 |
Acute Radiation Oral Mucositis in Nasopharyngeal Carcinoma(NPC) Patients Treated With Combined Radio-Chemotherapy |
https://ClinicalTrials.gov/show/NCT03720340 |
Recruiting |
Zhejiang Cancer Hospital |
2021-08-31 |
| NCT03708822 |
Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03708822 |
Recruiting |
Sun Yat-sen University |
2020-12-30 |
| NCT03701451 |
Demethylated Drug in the Treatment of Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03701451 |
Recruiting |
Guilin Medical University, China |
2020-12-01 |
| NCT03700476 |
Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03700476 |
Recruiting |
Sun Yat-sen University |
2023-01-31 |
| NCT03668730 |
Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03668730 |
Recruiting |
Sun Yat-sen University |
2023-12-30 |
| NCT03668366 |
S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03668366 |
Active, not recruiting |
Fudan University |
2018-12-01 |
| NCT03666221 |
Nimotuzumab for Recurrent Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03666221 |
Recruiting |
Fujian Cancer Hospital |
2020-04-01 |
| NCT03657017 |
PET/MR in Locally Advanced Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03657017 |
Recruiting |
Zhejiang Cancer Hospital |
2022-06-01 |
| NCT03656965 |
EBV Positive Nasopharyngeal Carcinoma Treated With Concurrent Chemo-radiotherapy With or Without Anti-Viral Drug |
https://ClinicalTrials.gov/show/NCT03656965 |
Active, not recruiting |
Kuwait Cancer Control Center |
2021-05-31 |
| NCT03639467 |
Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03639467 |
Recruiting |
Chinese Academy of Medical Sciences |
2021-08-22 |
| NCT03604965 |
GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC |
https://ClinicalTrials.gov/show/NCT03604965 |
Recruiting |
Guiyang Medical University |
2020-07-21 |
| NCT03601975 |
Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03601975 |
Recruiting |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-07-30 |
| NCT03598218 |
Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03598218 |
Recruiting |
Guilin Medical University, China |
2020-07-13 |
| NCT03578575 |
To Investigate the Molecular Mechanism of Traditional Chinese Medicine Constitution Using Next-generation Sequencing in Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03578575 |
Recruiting |
China Medical University Hospital |
2020-07-31 |
| NCT03574324 |
TPF Induction Chemotherapy vs PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC |
https://ClinicalTrials.gov/show/NCT03574324 |
Recruiting |
Guiyang Medical University |
2023-05-24 |
| NCT03558191 |
SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy. |
https://ClinicalTrials.gov/show/NCT03558191 |
Active, not recruiting |
Jiangsu HengRui Medicine Co., Ltd. |
2020-06-30 |
| NCT03557112 |
By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC |
https://ClinicalTrials.gov/show/NCT03557112 |
Recruiting |
Guiyang Medical University |
2021-06-01 |
| NCT03517488 |
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03517488 |
Recruiting |
Xencor, Inc. |
2020-12-31 |
| NCT03427827 |
Camrelizumab (PD-1 Antibody) After Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma (PACIFIC-NPC) |
https://ClinicalTrials.gov/show/NCT03427827 |
Recruiting |
Sun Yat-sen University |
2022-02-28 |
| NCT03427359 |
Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03427359 |
Completed |
The University of Hong Kong-Shenzhen Hospital |
2017-12-31 |
| NCT01249547 |
Nasopharyngeal Carcinoma (NPC) Axitinib |
https://ClinicalTrials.gov/show/NCT01249547 |
Completed |
Chinese University of Hong Kong |
2016-12-31 |
| NCT01187238 |
The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT01187238 |
Completed |
Chinese Academy of Medical Sciences |
2013-05-31 |
| NCT01155609 |
L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT01155609 |
Completed |
University of Washington |
2011-12-31 |
| NCT01094405 |
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy |
https://ClinicalTrials.gov/show/NCT01094405 |
Active, not recruiting |
Chinese University of Hong Kong |
2021-12-31 |
| NCT00982449 |
124I-FIAU Imaging in EBV and KSHV Associated Cancers |
https://ClinicalTrials.gov/show/NCT00982449 |
Completed |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2013-07-31 |
| NCT00953420 |
Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes |
https://ClinicalTrials.gov/show/NCT00953420 |
Completed |
Baylor College of Medicine |
2014-06-30 |
| NCT00939627 |
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab |
https://ClinicalTrials.gov/show/NCT00939627 |
Completed |
National Cancer Institute (NCI) |
2013-01-31 |
| NCT00896181 |
Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) |
https://ClinicalTrials.gov/show/NCT00896181 |
Active, not recruiting |
Stanford University |
2019-11-11 |
| NCT04425265 |
Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT04425265 |
Recruiting |
Sun Yat-sen University |
2024-06-30 |
| NCT04223024 |
Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT04223024 |
Recruiting |
Sun Yat-sen University |
2022-12-31 |
| NCT03866967 |
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03866967 |
Recruiting |
Akeso |
2020-06-15 |
| NCT03429868 |
PET and MRI in Prognosis Prediction of NPC |
https://ClinicalTrials.gov/show/NCT03429868 |
Recruiting |
Chang Gung Memorial Hospital |
2020-07-31 |
| NCT03213587 |
Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) |
https://ClinicalTrials.gov/show/NCT03213587 |
Recruiting |
Zhejiang Cancer Hospital |
2020-07-31 |
| NCT02795195 |
Trail Evaluating Carbon Ion Radiotherapy (3 GyE Per Fraction) for Locally Recurrent Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT02795195 |
Active, not recruiting |
Shanghai Proton and Heavy Ion Center |
2020-12-31 |
| NCT00834093 |
A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT00834093 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2020-12-31 |
| NCT04448522 |
Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT04448522 |
Recruiting |
Sun Yat-sen University |
2026-06-30 |
| NCT02948699 |
A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients |
https://ClinicalTrials.gov/show/NCT02948699 |
Active, not recruiting |
Zhejiang Cancer Hospital |
2018-11-30 |
| NCT00815087 |
Functional Electrical Stimulation in Irradiated Nasopharyngeal Carcinoma (NPC) |
https://ClinicalTrials.gov/show/NCT00815087 |
Completed |
National Taiwan University Hospital |
2009-02-28 |
| NCT04417985 |
Prognostic Utility of the Imaging and Biological Signatures in Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT04417985 |
Completed |
Chang Gung Memorial Hospital |
2014-07-31 |
| NCT03791944 |
3DV+TPS Applied to Radiotherapy for Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03791944 |
Recruiting |
Xinqiao Hospital of Chongqing |
2019-01-31 |
| NCT03612219 |
Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03612219 |
Recruiting |
Guilin Medical University, China |
2021-07-28 |
| NCT03306121 |
TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03306121 |
Recruiting |
Sun Yat-sen University |
2020-11-09 |
| NCT03082534 |
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03082534 |
Recruiting |
University of California, San Diego |
2019-12-30 |
| NCT03015727 |
Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT03015727 |
Recruiting |
Zhejiang Cancer Hospital |
2022-12-31 |
| NCT02578641 |
A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients |
https://ClinicalTrials.gov/show/NCT02578641 |
Active, not recruiting |
Tessa Therapeutics |
2021-02-28 |
| NCT02834013 |
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
https://ClinicalTrials.gov/show/NCT02834013 |
Recruiting |
National Cancer Institute (NCI) |
2021-08-31 |
| NCT04384627 |
Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy |
https://ClinicalTrials.gov/show/NCT04384627 |
Active, not recruiting |
Sun Yat-sen University |
2020-10-01 |
| NCT00778908 |
Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT00778908 |
Completed |
Guangxi Medical University |
2011-01-31 |
| NCT00747799 |
Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) |
https://ClinicalTrials.gov/show/NCT00747799 |
Completed |
Sun Yat-sen University |
2011-05-31 |
| NCT00717184 |
A Pilot Study of Autologous Ex Vivo Activated NK Cell Infusion in the Treatment of Metastatic Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT00717184 |
Completed |
National University Hospital, Singapore |
NA |
| NCT00706316 |
Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer |
https://ClinicalTrials.gov/show/NCT00706316 |
Completed |
University Health Network, Toronto |
2009-08-31 |
| NCT00700440 |
Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy |
https://ClinicalTrials.gov/show/NCT00700440 |
Completed |
Sun Yat-sen University |
2009-04-30 |
| NCT00697905 |
Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT00697905 |
Completed |
Ministry of Health, Malaysia |
2011-05-31 |
| NCT00697619 |
To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer |
https://ClinicalTrials.gov/show/NCT00697619 |
Completed |
Sun Yat-sen University |
2009-01-31 |
| NCT00630149 |
Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy |
https://ClinicalTrials.gov/show/NCT00630149 |
Completed |
Sun Yat-sen University |
2011-11-30 |
| NCT00609219 |
T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC |
https://ClinicalTrials.gov/show/NCT00609219 |
Completed |
Baylor College of Medicine |
2007-10-31 |
| NCT00603915 |
A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer |
https://ClinicalTrials.gov/show/NCT00603915 |
Completed |
University Health Network, Toronto |
2010-12-31 |
| NCT00592501 |
Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT00592501 |
Completed |
Massachusetts General Hospital |
2019-04-30 |
| NCT00565448 |
Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents |
https://ClinicalTrials.gov/show/NCT00565448 |
Completed |
Sanofi |
2009-03-31 |
| NCT00535795 |
Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA |
https://ClinicalTrials.gov/show/NCT00535795 |
Completed |
King Faisal Specialist Hospital & Research Center |
2015-09-30 |
| NCT00516087 |
LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA) |
https://ClinicalTrials.gov/show/NCT00516087 |
Completed |
Baylor College of Medicine |
2012-12-31 |
| NCT00513435 |
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT00513435 |
Completed |
National Cancer Institute (NCI) |
2011-03-31 |
| NCT00507767 |
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT00507767 |
Completed |
National Cancer Institute (NCI) |
2010-02-28 |
| NCT00492089 |
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT00492089 |
Completed |
National Cancer Institute (NCI) |
2010-08-31 |
| NCT00470496 |
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT00470496 |
Completed |
Roswell Park Cancer Institute |
2011-10-28 |
| NCT00454142 |
Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer |
https://ClinicalTrials.gov/show/NCT00454142 |
Completed |
National Cancer Institute (NCI) |
2010-04-30 |
| NCT00439426 |
A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer. |
https://ClinicalTrials.gov/show/NCT00439426 |
Completed |
Hoffmann-La Roche |
2009-09-30 |
| NCT00436800 |
Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT00436800 |
Completed |
Sanofi |
2008-10-31 |
| NCT00436293 |
Taxotere + Cisplatin in Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT00436293 |
Completed |
Sanofi |
2010-03-31 |
| NCT00431210 |
Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT00431210 |
Completed |
Dana-Farber Cancer Institute |
2015-06-30 |
| NCT00430378 |
Acupuncture for Prevention of Radiation-Induced Xerostomia |
https://ClinicalTrials.gov/show/NCT00430378 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2021-01-31 |
| NCT00410826 |
Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT00410826 |
Completed |
University of Washington |
2012-05-31 |
| NCT00408694 |
Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer |
https://ClinicalTrials.gov/show/NCT00408694 |
Completed |
National Cancer Institute (NCI) |
2011-12-15 |
| NCT00397384 |
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer |
https://ClinicalTrials.gov/show/NCT00397384 |
Completed |
National Cancer Institute (NCI) |
2013-06-30 |
| NCT00387335 |
Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT00387335 |
Completed |
National Cancer Institute (NCI) |
2010-03-31 |
| NCT00379262 |
Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT00379262 |
Completed |
Hong Kong Nasopharyngeal Cancer Study Group Limited |
2017-05-31 |
| NCT00370890 |
A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy |
https://ClinicalTrials.gov/show/NCT00370890 |
Active, not recruiting |
Chinese University of Hong Kong |
2020-12-31 |
| NCT00305734 |
Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer |
https://ClinicalTrials.gov/show/NCT00305734 |
Completed |
National Cancer Institute (NCI) |
2007-07-31 |
| NCT00274937 |
Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer |
https://ClinicalTrials.gov/show/NCT00274937 |
Active, not recruiting |
Children’s Oncology Group |
2016-03-31 |
| NCT00212108 |
A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839 |
https://ClinicalTrials.gov/show/NCT00212108 |
Completed |
National University Hospital, Singapore |
2007-03-31 |
| NCT00201396 |
A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma |
https://ClinicalTrials.gov/show/NCT00201396 |
Completed |
National Health Research Institutes, Taiwan |
2009-08-31 |
| NCT00141765 |
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers |
https://ClinicalTrials.gov/show/NCT00141765 |
Completed |
University of Michigan Rogel Cancer Center |
2008-12-31 |
| NCT00123864 |
Study Using Intensity-modulated Radiation Therapy in Patients With Nasopharynx Cancer to Permit Sparing of Contralateral Parotid Gland Function |
https://ClinicalTrials.gov/show/NCT00123864 |
Completed |
AHS Cancer Control Alberta |
NA |
| NCT00114283 |
Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT00114283 |
Completed |
National Cancer Institute (NCI) |
2006-10-31 |
| NCT00103259 |
Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00103259 |
Completed |
National Cancer Institute (NCI) |
2011-11-30 |
| NCT00101348 |
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT00101348 |
Completed |
National Cancer Institute (NCI) |
2007-10-31 |
| NCT00101270 |
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00101270 |
Completed |
National Cancer Institute (NCI) |
2007-09-30 |
| NCT00098631 |
Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT00098631 |
Completed |
National Cancer Institute (NCI) |
2006-12-31 |
| NCT00096512 |
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT00096512 |
Completed |
National Cancer Institute (NCI) |
2006-05-31 |
| NCT00091182 |
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment |
https://ClinicalTrials.gov/show/NCT00091182 |
Completed |
National Cancer Institute (NCI) |
2006-02-28 |
| NCT00089362 |
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors |
https://ClinicalTrials.gov/show/NCT00089362 |
Completed |
National Cancer Institute (NCI) |
2008-01-31 |
| NCT00078546 |
EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) |
https://ClinicalTrials.gov/show/NCT00078546 |
Completed |
Baylor College of Medicine |
2007-01-31 |
| NCT00078494 |
Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer |
https://ClinicalTrials.gov/show/NCT00078494 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00004074 |
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu |
https://ClinicalTrials.gov/show/NCT00004074 |
Completed |
National Cancer Institute (NCI) |
2009-02-28 |
| NCT00068497 |
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT00068497 |
Completed |
National Cancer Institute (NCI) |
2007-12-31 |
| NCT00063895 |
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00063895 |
Completed |
National Cancer Institute (NCI) |
2005-10-31 |
| NCT00057785 |
Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer |
https://ClinicalTrials.gov/show/NCT00057785 |
Completed |
Radiation Therapy Oncology Group |
2007-02-28 |
| NCT00055913 |
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT00055913 |
Completed |
National Cancer Institute (NCI) |
2007-09-30 |
| NCT00049283 |
Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT00049283 |
Completed |
National Cancer Institute (NCI) |
2008-02-29 |
| NCT00031681 |
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) |
https://ClinicalTrials.gov/show/NCT00031681 |
Completed |
National Cancer Institute (NCI) |
2011-01-31 |
| NCT00023959 |
Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT00023959 |
Completed |
National Cancer Institute (NCI) |
2010-03-31 |
| NCT00055770 |
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT00055770 |
Completed |
National Cancer Institute (NCI) |
2006-12-31 |
| NCT00030498 |
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction |
https://ClinicalTrials.gov/show/NCT00030498 |
Completed |
National Cancer Institute (NCI) |
2007-07-31 |